Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Fig. 2

Best change from baseline in the sum of longest diameters of target lesions. CRC, colorectal cancer; HirPD, immune-related progressive disease; irSD, immune-related stable disease. aPatient experienced clinical progression with new brain metastasis (off schedule scan) after the primary lesions showed decreases in size. bBecause patient’s only postbaseline scan was an abdominal CT. CRC, colorectal cancer; NSCLC, non–small-cell lung cancer; SCCHN, squamous cell carcinoma of the head and neck; TCC, transitional carcinoma of the bladder

Back to article page